GlassScriptPhysician profile
Homer E Breckenridge
NPI 1649371790
$2,274.43
in general payments reported to CMS, 2019-2025
20 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $218 · 2021: $421 · 2022: $619 · 2023: $267 · 2024: $209 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $750.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $317.56 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Medical Device Business Services, INC. | $312.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $150.49 | 2020-2023 | Livalo, Seglentis |
| Abbvie INC. | $105.77 | 2021-2022 | |
| Elucent Medical | $105.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $83.58 | 2020-2025 | Airsupra |
| Ethicon US, LLC | $59.69 | 2019 | |
| Eisai INC. | $56.41 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $45.53 | 2021-2023 | Dupixent |
| Genzyme Corporation | $44.99 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.74 | 2022-2023 | |
| Lilly USA, LLC | $42.29 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.23 | 2024 | |
| Merck Sharp & Dohme LLC | $32.07 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $23.90 | 2025 | Auvelity |
| Averitas Pharma INC. | $22.42 | 2025 | Qutenza |
| Allergan, INC. | $15.60 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.43 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Homer Breckenridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.